ESMO Congress 2021

Sarmad Sadeghi talks about their phase 2 trial pointing to the potential of combining the novel EphrinB2 pathway inhibitor sEphB4-HSA with pembrolizumab in previously treated patients with metastatic urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Guru Sonpavde outlines the findings of their immunotherapy study supporting a potential role for longitudinal ctDNA profiling to identify suitable therapies for people with metastatic urothelial cancer.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany